HPGC(SH:600664) Xin Lang Cai Jing·2026-02-10 07:44Core Viewpoint - The company announced that its subsidiary, Harbin Pharmaceutical Group, received approval from the National Medical Products Administration for the injectable Cefotaxime Sodium (1.0g, 0.5g), which has passed the consistency evaluation for generic drugs [1] Group 1: Product Approval and Market Impact - The approved drug is indicated for various infections, which may enhance the company's product portfolio [1] - The projected domestic sales for 2024 are estimated at 1.55 billion yuan, with 889 million yuan expected in the first three quarters of 2025 [1] - The company has invested approximately 8.1573 million yuan in research and development for this product [1] Group 2: Competitive Position and Future Prospects - Passing the consistency evaluation is expected to help expand the drug's market share and improve competitiveness [1] - The company acknowledges that drug sales are influenced by multiple factors, indicating potential uncertainties in future performance [1]